{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:51:01Z","timestamp":1789573861997,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.juro.2017.04.077","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T04:30:55Z","timestamp":1492576255000},"page":"824-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population"],"prefix":"10.1097","volume":"198","author":[{"given":"Kourosh","family":"Ravvaz","sequence":"first","affiliation":[{"name":"Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin"},{"name":"Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus E.","family":"Walz","sequence":"additional","affiliation":[{"name":"Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin"},{"name":"Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Weissert","sequence":"additional","affiliation":[{"name":"Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin"},{"name":"Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy M.","family":"Downs","sequence":"additional","affiliation":[{"name":"Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin"},{"name":"Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.04.077_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.juro.2017.04.077_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib4","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Gu\u00e9rin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer","volume":"11","author":"Clark","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.juro.2017.04.077_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","article-title":"Concordance for prognostic models with competing risks","volume":"15","author":"Wolbers","year":"2014","journal-title":"Biostatistics"},{"key":"10.1016\/j.juro.2017.04.077_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.juro.2017.04.077_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.juro.2017.04.077_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1472-6947-8-53","article-title":"Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers","volume":"8","author":"Vickers","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.juro.2017.04.077_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2017.04.077_bib13","doi-asserted-by":"crossref","first-page":"e96849","DOI":"10.1371\/journal.pone.0096849","article-title":"Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours","volume":"9","author":"Vedder","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.juro.2017.04.077_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urology.2013.04.007","article-title":"Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC\u00a0and CUETO scoring models","volume":"82","author":"Xu","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.04.077_bib15","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Gu\u00e9rin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2014.633","article-title":"Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients","volume":"112","author":"Orsola","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2017.04.077_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2015.09.005","article-title":"EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice?","volume":"14","author":"Busato","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2017.04.077_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.eururo.2011.06.001","article-title":"How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?","volume":"60","author":"Sylvester","year":"2011","journal-title":"Eur Urol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.04.077_bib20","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1038\/modpathol.2008.235","article-title":"The current classification of urothelial neoplasms","volume":"22","author":"Grignon","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.juro.2017.04.077_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410x.2000.00356.x","article-title":"Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer","volume":"85","author":"Tosoni","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2017.04.077_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2011.10571.x","volume":"109","author":"Mariappan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2017.04.077_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/iju.12749","article-title":"Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute: risk factors of T1HG-BC","volume":"22","author":"Miyake","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4111\/kju.2014.55.10.643","article-title":"Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models","volume":"55","author":"Choi","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.juro.2017.04.077_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717547850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717547850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.04.077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:02:35Z","timestamp":1651194155000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.04.077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1016\/j.juro.2017.04.077"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.077","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}